Work

Bevacizumab, TAS-102, and irinotecan in oxaliplatin and fluoropyrimidine pre-treated metastatic colorectal cancer (BEV-TASIRI): A single-arm, prospective, multicenter study and comparison with BEV-FOLFIRI/XELIRI using inverse probability of treatment weighting.

Year: 2025

Type: conference-abstract

Study design: Clinical Trial

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.e15571

Authors: Xiangling Wang, Jian Wang, Cuihua Yi, Wenfei Han, Yawei Wang, Linli Qu, Jian Chen, Jing Lv, Yong Cui, Mianli Li, Feng Wang, Xiaorong Yang, Jing Hao

Institutions: Shandong University, Qilu Hospital of Shandong University, Qingdao University, Yuhuangding Hospital, Affiliated Hospital of Qingdao University, Binzhou Medical University

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Qilu Hospital of Shandong University

OpenAlex ID: W4410821676

Cites:

Cited by:

Related to: 10